Bernard E. Bihain
Bernard E. Bihain is Chairman and CSO of Genclis. He graduated as Medical Doctor from the Université Libre De Bruxelles (ULB) in 1984 and has over 20 years of experience in scientific research. His background encompasses, amongst others, the discovery of the second apoB-E lipoprotein receptor, a major molecular link between obesity hyper-lipoproteinemia and possibly cancer, the discovery of FAMOXIN, the lead therapeutic protein of Genset SA and the discovery of increased transcription infidelity (TI) in cancer leading to novel methods for cancer severity assessment and companion diagnosis.
In 2004, Bernard Bihain co-founded Genclis SAS, a biotechnology company that offers genetic research for conditions such as metabolism-related illnesses, diabetes, and cancer.